Leslie M Shaw

List of Publications by Year
in descending order

Version: 2024-02-01

190 papers	21,016 citations	28242 55 h-index	10724 138 g-index
214 all docs	214 docs citations	214 times ranked	19122 citing authors

#	Article	IF	Citations
1	Stateâ€ofâ€theâ€art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.4	33
2	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
3	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.4	17
4	Characterization of preâ€analytical sample handling effects on a panel of Alzheimer's diseaseâ€“related bloodâ€based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.4	84
5	Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers. Annals of Clinical and Translational Neurology, 2022, 9, 155-170.	1.7	17
6	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
7	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimerâ€™s Disease to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1155-1167.	1.5	9
8	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
9	Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	9
10	Performance of Two Fentanyl Immunoassays against a Liquid Chromatographyâ€“Tandem Mass Spectrometry Method. Journal of Analytical Toxicology, 2021, 45, 117-123.	1.7	6
11	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, 822-830.	0.4	27
12	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimerâ€™s Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	4.1	186
13	Alzheimerâ€™s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans. Alzheimer's Research and Therapy, 2021, 13, 22.	3.0	15
14	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
15	Evaluation of a Nanoparticle-Based Busulfan Immunoassay for Rapid Analysis on Routine Clinical Analyzers. Therapeutic Drug Monitoring, 2021, 43, 766-771.	1.0	4
16	Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1976-1987.	0.4	35
17	Mass spectrometryâ€based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. Journal of Neurochemistry, 2021, 159, 211-233.	2.1	29
18	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Movement Disorders, 2021, 36, 2945-2950.	2.2	63

#	Article	IF	Citations
19	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5
20	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
21	CSF and blood plasma mass spectrometry measures of AÎ², tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
22	Racial differences in AD CSF biomarkers in persons with MCI: Implications and insights. Alzheimer's and Dementia, 2021, 17, .	0.4	0
23	Comparative analytical performance of multiple plasma amyloidâ€beta assays and their relationship to amyloid PET. Alzheimer's and Dementia, 2021, 17, .	0.4	1
24	Stability of the novel bloodâ€based biomarkers under preâ€analytical sample handling conditions: Results of the SABBâ€GBSC working group. Alzheimer's and Dementia, 2021, 17, .	0.4	0
25	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
26	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
27	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	4.9	94
28	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. journal of applied laboratory medicine, The, 2020, 5, 183-193.	0.6	10
29	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
30	Association of CSF AÎ², amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology, 2020, 95, e2075-e2085.	1.5	31
31	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. Alzheimer's and Dementia, 2020, 16, 1234-1247.	0.4	15
32	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	3.3	73
33	Perceived Stress is Associated with Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 77, 843-853.	1.2	7
34	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. Annals of Clinical and Translational Neurology, 2020, 7, 2342-2355.	1.7	20
35	Effect of escitalopram dose and treatment duration on CSF AÎ² levels in healthy older adults. Neurology, 2020, 95, e2658-e2665.	1.5	28
36	First amyloid Î²1â€42 certified reference material for reâ€calibrating commercial immunoassays. Alzheimer's and Dementia, 2020, 16, 1493-1503.	0.4	42

#	Article	IF	Citations
37	Normalization of CSF pTau measurement by AÎ²40 improves its performance as a biomarker of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 97.	3.0	31
38	Webâ€based requisitioning, tracking and laboratory result reporting system for clinical trials using a central laboratory. Alzheimer's and Dementia, 2020, 16, e038627.	0.4	0
39	CSF pâ€Tau/AÎ² 40 ratio adjusts for the variance of CSF production and predicts brain tau accumulation in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e038679.	0.4	0
40	ATN classifications in a mixed cohort of frontotemporal lobar degeneration (FTLD) and Alzheimerâ€™s disease (AD) pathology using cerebrospinal fluid neurofilament light chain (NFL). Alzheimer's and Dementia, 2020, 16, e039144.	0.4	0
41	Higher CSF STREM2/Pâ€tau ratio levels attenuate effects of polygenic Alzheimerâ€™s disease risk on cognitive decline and neurodegeneration. Alzheimer's and Dementia, 2020, 16, e044800.	0.4	0
42	A biorepository for the inâ€depth validation of preâ€analytical sample handling effects on novel bloodâ€based biomarkers for Alzheimerâ€™s disease: The first results. Alzheimer's and Dementia, 2020, 16, e045763.	0.4	3
43	Ultraâ€performance liquid chromatographyâ€tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. Alzheimer's and Dementia, 2020, 16, e040373.	0.4	0
44	Maximizing Safety in the Conduct of Alzheimerâ€™s Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31.	1.2	8
45	Sex and APOE Îµ4 genotype modify the Alzheimerâ€™s disease serum metabolome. Nature Communications, 2020, 11, 1148.	5.8	115
46	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€Sectional Study. Movement Disorders, 2020, 35, 833-844.	2.2	48
47	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LCâ€“MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	1.5	15
48	A Biomarker for Concussion: The Good, the Bad, and the Unknown. journal of applied laboratory medicine, The, 2020, 5, 170-182.	0.6	3
49	18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 589-601.	1.2	7
50	Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 563-578.	1.2	5
51	Antibodyâ€based methods for the measurement of Î±â€synuclein concentration in human cerebrospinal fluid â€“ method comparison and round robin study. Journal of Neurochemistry, 2019, 149, 126-138.	2.1	44
52	Sex differences in the genetic predictors of Alzheimerâ€™s pathology. Brain, 2019, 142, 2581-2589.	3.7	65
53	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	2.8	142
54	Longitudinal analyses of cerebrospinal fluid Î±â€Synuclein in prodromal and early Parkinson's disease. Movement Disorders, 2019, 34, 1354-1364.	2.2	89

#	Article	IF	Citations
55	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	192
56	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
57	The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. Journal of the American Geriatrics Society, 2019, 67, 794-798.	1.3	43
58	ElecsysÂ® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
59	Method comparison study of the ElecsysÂ® Î²-Amyloid (1â€“42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	0.8	30
60	APOE Effect on Amyloid-Î² PET Spatial Distribution, Deposition Rate, and Cut-Points. Journal of Alzheimer's Disease, 2019, 69, 783-793.	1.2	15
61	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
62	Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 263-276.	1.2	13
63	O4â€03â€01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA. Alzheimer's and Dementia, 2019, 15, P1234.	0.4	0
64	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys Aî²(1â€“42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
65	Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment. JAMA Network Open, 2019, 2, e1917363.	2.8	66
66	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	4.4	253
67	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.4	302
68	Elevated CSF GAPâ€43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
69	Altered bile acid profile associates with cognitive impairment in Alzheimer's diseaseâ€”An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.4	396
70	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.4	198
71	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
72	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468

#	Article	IF	Citations
73	Measurements of autoâ€antibodies to Î±â€synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. Journal of Neurochemistry, 2018, 145, 489-503.	2.1	47
74	A Longitudinal Study of Total and Phosphorylated Î±-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1541-1553.	1.2	29
75	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
76	Cerebrospinal fluid Î±â€synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1052-1062.	0.4	34
77	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	4.5	54
78	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
79	APOE, thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	2.2	35
80	P3â€213: MORE POWERFUL STATISTICAL APPROACHES FOR LONGITUDINAL COMPARISONS OF AD SUBTYPES ON CSF AND IMAGING BIOMARKERS FROM DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) AND ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI). Alzheimer's and Dementia, 2018, 14, P1152.	0.4	0
81	P1â€398: PARIETAL LOBE CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH LOWER CEREBROSPINAL FLUID BETA AMYLOID _{1â€42} IN PATIENTS WITH SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P454.	0.4	0
82	P2â€091: ASSAY PERFORMANCE MONITORING FOR AD BIOMARKERS USING POOLED CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2018, 14, P702.	0.4	0
83	P3â€026: DIFFERENTIAL EFFECT OF PROSPECTIVE ESCITALOPRAM DECREASE ON LONGITUDINAL CSF AB CONCENTRATION IN AMYLOID (+) VERSUS AMYLOID (â€) COGNITIVELY NORMAL ELDERLY INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P1074.	0.4	0
84	P3â€267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P1178.	0.4	1
85	P3â€069: CHOLESTEROL EFFLUX CAPACITY (CEC) IN PLASMA AND CEREBROSPINAL FLUID (CSF) OF PATIENTS WITH ALZHEIMER'S DISEASE (AD) AND MILD COGNITIVE IMPAIRMENT (MCI) AND COMPARISON SUBJECTS: EFFECTS OF GENDER AND DIAGNOSIS. Alzheimer's and Dementia, 2018, 14, P1090.	0.4	1
86	P2â€261: APOLIPOPROTEIN J/CLUSTERIN IS THE PRIMARY DETERMINANT OF THE CHOLESTEROL EFFLUX CAPACITY OF CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2018, 14, P776.	0.4	0
87	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
88	P1â€281: NONLINEAR Nâ€SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET. Alzheimer's and Dementia, 2018, 14, P390.	0.4	1
89	P1â€143: MULTIVARIATE GENOMEâ€WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION. Alzheimer's and Dementia, 2018, 14, P330.	0.4	0
90	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.4	0

#	Article	IF	Citations
91	P1â€026: CEREBROSPINAL FLUID TAU, AÎ², AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. Alzheimer's and Dementia, 2018, 14, P275.	0.4	0
92	O2â€14â€01: CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL. Alzheimer's and Dementia, 2018, 14, P656.	0.4	0
93	P1â€255: ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LCâ€MSâ€MS REFERENCE METHOD. Alzheimer's and Dementia, 2018, 14, P378.	0.4	0
94	P1â€419: USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P465.	0.4	0
95	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
96	O2â€09â€04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF Î±â€SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH. Alzheimer's and Dementia, 2018, 14, P642.	0.4	0
97	Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-Î²1-42 and Hypertension. Journal of Alzheimer's Disease, 2018, 66, 1095-1104.	1.2	21
98	Derivation of cutoffs for the Elecsys^{Â®} amyloid Î² (1â€“42) assay in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 698-705.	1.2	50
99	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
100	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 98.	3.0	25
101	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521.	0.4	163
102	DTâ€02â€01: APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1668.	0.4	0
103	P1â€288: THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)â€ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) COMPARISON STUDY: CHALLENGES AND OPPORTUNITIES. Alzheimer's and Dementia, 2018, 14, P395.	0.4	1
104	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
105	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
106	Cerebrospinal fluid tau, AÎ², and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1159-1170.	0.4	96
107	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288.	2.2	122
108	CSF AÎ²1â€“42 â€“ an excellent but complicated Alzheimer's biomarker â€“ a route to standardisation. Clinica Chimica Acta, 2017, 467, 27-33.	0.5	104

#	Article	IF	Citations
109	Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease. NeuroImage: Clinical, 2017, 13, 106-115.	1.4	48
110	CSF biomarkers for Alzheimer disease â€" approaching consensus. Nature Reviews Neurology, 2017, 13, 131-132.	4.9	26
111	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimerâ€™s Disease Markers in Elderly Healthy Participants. Journal of Alzheimer's Disease, 2017, 56, 1437-1449.	1.2	28
112	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
113	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1245-1254.	1.2	54
114	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.4	213
115	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.4	362
116	Genome-wide, high-content siRNA screening identifies the Alzheimerâ€™s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathologica, 2017, 133, 955-966.	3.9	60
117	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	1.5	70
118	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	2.8	51
119	Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults. Neurobiology of Aging, 2017, 58, 102-111.	1.5	15
120	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
121	[P1â€“254]: CHARACTERISTICS AND PROGRESS ON THE INITIAL 209 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL. Alzheimer's and Dementia, 2017, 13, P345.	0.4	0
122	The Effect of Propofol vs. Isoflurane Anesthesia on Postoperative Changes in Cerebrospinal Fluid Cytokine Levels: Results from a Randomized Trial. Frontiers in Immunology, 2017, 8, 1528.	2.2	32
123	Cerebrospinal fluid biomarkers and clinical features in leucineâ€rich repeat kinase 2 (LRRK2) mutation carriers. Movement Disorders, 2016, 31, 906-914.	2.2	29
124	The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimerâ€™s Disease: Results of a Randomized Trial. Journal of Alzheimer's Disease, 2016, 52, 1299-1310.	1.2	49
125	F1â€02â€01: The Alzheimerâ€™s Metabolome: Relationship to Pathological Markers and Cognitive Decline in the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI). Alzheimer's and Dementia, 2016, 12, P164.	0.4	0
126	F1-02-02: Genetic Influence on Levels of Targeted Metabolites Associated with Alzheimerâ€™s Disease. , 2016, 12, P164-P165.		0

#	Article	IF	Citations
127	O1â€10â€04: Escitalopram Decreases Longitudinal CSF ABETA Concentration in Cognitively Normal Subjects age 60â€85. Alzheimer's and Dementia, 2016, 12, P199.	0.4	0
128	O3â€12â€01: Both Odor Identification and Amyloid Status Predict Memory Decline in Older Adults. Alzheimer's and Dementia, 2016, 12, P316.	0.4	0
129	S4â€01â€02: Progress in Standardization and Implementation of CSF Biomarkers in Clinical Trials and Routine Practice. Alzheimer's and Dementia, 2016, 12, P321.	0.4	0
130	Profiling the dynamics of CSF and plasma AÎ² reduction after treatment with JNJâ€54861911, a potent oral BACE inhibitor. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 202-212.	1.8	50
131	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
132	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology, 2016, 87, 1227-1234.	1.5	25
133	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P252.	0.4	0
134	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	0.7	20
135	Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 463-470.	1.2	1
136	Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. Neurobiology of Disease, 2016, 94, 10-17.	2.1	37
137	CSF biomarkers associated with disease heterogeneity in early Parkinsonâ€™s disease: the Parkinsonâ€™s Progression Markers Initiative study. Acta Neuropathologica, 2016, 131, 935-949.	3.9	190
138	Round robin test on quantification of amyloidâ€Î² 1â€“42 in cerebrospinal fluid by mass spectrometry. Alzheimer's and Dementia, 2016, 12, 55-59.	0.4	46
139	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	4.5	354
140	An Alzheimerâ€™s Disease-Derived Biomarker Signature Identifies Parkinsonâ€™s Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	1.1	25
141	CSF betaâ€amyloid 1â€“42 â€“ what are we measuring in Alzheimer's disease?. Annals of Clinical and Translational Neurology, 2015, 2, 131-139.	1.7	34
142	Validation of the Erlangen Score Algorithm for the Prediction of the Development ofÂDementia due to Alzheimerâ€™s Disease inÂPre-Dementia Subjects. Journal of Alzheimer's Disease, 2015, 48, 433-441.	1.2	41
143	Independent information from cerebrospinal fluid amyloid-Î² and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
144	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.4	261

#	Article	IF	Citations
145	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.4	181
146	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.4	79
147	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
148	Memory, executive, and multidomain subtle cognitive impairment. Neurology, 2015, 85, 144-153.	1.5	42
149	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.4	157
150	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiology of Disease, 2015, 80, 29-41.	2.1	71
151	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 Î²-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurology, 2015, 72, 571.	4.5	87
152	The transitional association between Î²â€amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.4	37
153	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimerâ€™s disease. Brain, 2015, 138, 3373-3385.	3.7	200
154	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiology of Aging, 2015, 36, 273-282.	1.5	30
155	Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies. Korean Journal of Physiology and Pharmacology, 2014, 18, 447.	0.6	13
156	Emerging Î²-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
157	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug and Alcohol Dependence, 2014, 142, 262-268.	1.6	25
158	Association of plasma and cortical amyloid beta is modulated by APOE Îµ4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.4	43
159	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. NeuroImage: Clinical, 2014, 4, 461-472.	1.4	45
160	Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. NeuroImage: Clinical, 2014, 4, 164-173.	1.4	112
161	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.4	51
162	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-Î²42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. Journal of Alzheimer's Disease, 2014, 41, 441-451.	1.2	94

#	Article	IF	Citations
163	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimer's Research and Therapy, 2014, 6, 36.	3.0	26
164	P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET. , 2014, 10, P636-P636.		0
165	P4-054: ASSOCIATION OF PLASMA LEPTIN/ADIPONECTIN RATIO IN MEN WITH CSF BIOMARKERS IN THE ADNI-1 COHORT. , 2014, 10, P801-P802.		0
166	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3
167	P4-058: IMPACT OF ANALYTICAL BIAS AND IMPRECISION OF CSF BIOMARKERS ON THEIR CLINICAL DIAGNOSTIC PERFORMANCE FOR AD DIAGNOSIS. , 2014, 10, P803-P803.		0
168	P4-237: WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT. , 2014, 10, P873-P874.		0
169	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	4.9	3,378
170	Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimer's Research and Therapy, 2013, 5, 8.	3.0	113
171	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
172	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
173	Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-Î²1â€“42 and Ï„ Proteins as Alzheimer Disease Biomarkers. Clinical Chemistry, 2013, 59, 903-916.	1.5	139
174	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
175	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. Therapeutic Innovation and Regulatory Science, 2013, 47, 632-638.	0.8	7
176	Longitudinal plasma amyloid beta as a biomarker of Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 843-850.	1.4	54
177	Transforming cerebrospinal fluid AÎ²42 measures into calculated Pittsburgh compound B units of brain AÎ² amyloid. , 2011, 7, 133-141.		85
178	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
179	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica, 2011, 121, 597-609.	3.9	256
180	Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net. Lecture Notes in Computer Science, 2011, 7012, 27-34.	1.0	53

#	Article	IF	Citations
181	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	4.9	3,792
182	Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease. , 2010, 2010, 241-244.		2
183	Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging, 2010, 31, 1340-1354.	1.5	95
184	O3-03-01: Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort. , 2010, 6, S129-S129.		1
185	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 2009, 65, 403-413.	2.8	1,803
186	PENN Biomarker Core of the Alzheimerâ€™s Disease Neuroimaging Initiative. NeuroSignals, 2008, 16, 19-23.	0.5	46
187	Determination of Paroxetine in Plasma by Liquid Chromatography Coupled to Tandem Mass Spectrometry for Pharmacokinetic and Bio equivalence Studies. Arzneimittelforschung, 2007, 57, 455-461.	0.5	7
188	Suppression of Proliferation and Phosphorylation of Jak3 and STAT5 in Malignant T-cell Lymphoma Cells By Derivatives of Octylamino-Undecyl-Dimethylxanthine. Leukemia and Lymphoma, 1998, 28, 551-560.	0.6	20
189	Cyclosporine: Structure, Pharmacokinetics, and Therapeutic Drug Monitoring. CRC Critical Reviews in Clinical Laboratory Sciences, 1987, 25, 275-312.	1.0	52
190	Two-Directional Immunoelectrophoresis: Technique and Applications in the Clinical Laboratory. Separation Science, 1973, 8, 123-142.	0.7	0